Abstract
Individualizing treatment is key to improve outcome and reduce long-term side-effects in any cancer. In Hodgkin lymphoma (HL), individualization of treatment is hindered by a lack of genomic characterization and technology for sensitive, molecular response assessment.
Sequencing of cell-free (cf)DNA is a powerful strategy to understand an individual cancer genome and can be used to develop assays for extremely sensitive disease monitoring. In HL, a high proportion of cfDNA is tumor-derived making it a highly relevant disease model to study the role of cfDNA sequencing in cancer.
Here, we introduce our targeted cfDNA sequencing platform and present the largest genomic landscape of HL to date, which was entirely derived by cfDNA sequencing. We comprehensively genotype and assess minimal residual disease in 324 samples from 121 patients, presenting an integrated landscape of mutations and copy number variations in HL. In addition, we perform a deep analysis of mutational processes driving HL, investigate the clonal structure of HL and link several genotypes to HL phenotypes and outcome. Finally, we show that minimal residual disease assessment by repeat cfDNA sequencing as early as a week after treatment initiation is feasible and predicts overall treatment response allowing highly improved treatment guidance and relapse prediction. Our study also serves as a blueprint showcasing the utility of our platform for other cancers with similar therapeutic challenges.
Competing Interest Statement
PJB reports research grants from BeiGene, Bristol Myers Squibb, Merck Sharpe & Dohme, and Takeda; and personal fees and non-financial support from Bristol-Myers Squibb, Celgene and Takeda, all outside the submitted work. STS received travel grants from GSK. DMP reports being founder and CSO of Exbiome and an occasional advisor for Takeda. BvT reports personal fees and nonfinancial support from Bristol-Myers Squibb; personal fees from Amgen, Pfizer, Gilead Sciences, Pentixapharm, and Roche; grants, personal fees, and nonfinancial support from MSD and Takeda; and grants, personal fees, and nonfinancial support from Novartis. SB reports being founder, CEO and shareholder of Liqomics and personal fees and non-financial support from Bristol-Myers Squibb and Takeda outside the submitted work.
Funding Statement
SS was supported by a Mildred Scheel School of Oncology Aachen-Bonn-Cologne-Duesseldorf MD Research Stipend. Sequencing infrastructure was supported by DFG Research Infrastructure as part of the Next Generation Sequencing Competence Network [423957469]; NGS analyses were carried out at the production site WGGC Cologne. The research was partly funded by grant 70112502 from Deutsche Krebshilfe, grant EN 179/13-1 from the Deutsche Forschungsgemeinschaft (DFG) and a grant by the Frau-Weiskam und Christel Ruranski-Stiftung. It was also supported by the Hodgkin Lymphoma MRD consortium.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All patients provided written informed consent to allow the collection of peripheral blood for research purposes. All human subject research was performed in accordance with approved protocols by the local ethics committees and the Declaration of Helsinki. The study was approved by the ethics committee of the University of Cologne (No. 16-008, 16-444 and 18-360) and the ethics committee of the VUmc Amsterdam (No. 2017.008 and 2018.359).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding sources: SS was supported by a Mildred Scheel School of Oncology Aachen-Bonn-Cologne-Düsseldorf MD Research Stipend. Sequencing infrastructure was supported by DFG Research Infrastructure as part of the Next Generation Sequencing Competence Network [423957469]; NGS analyses were carried out at the production site WGGC Cologne. The research was partly funded by grant 70112502 from Deutsche Krebshilfe, grant EN 179/13-1 from the Deutsche Forschungsgemeinschaft (DFG) and a grant by the Frau-Weiskam und Christel Ruranski-Stiftung. It was also supported by the Hodgkin Lymphoma MRD consortium.
Conflict of Interest: PJB reports research grants from BeiGene, Bristol Myers Squibb, Merck Sharpe & Dohme, and Takeda; and personal fees and non-financial support from Bristol-Myers Squibb, Celgene and Takeda, all outside the submitted work. STS received travel grants from GSK. DMP reports being founder and CSO of Exbiome and an occasional advisor for Takeda. BvT reports personal fees and nonfinancial support from Bristol-Myers Squibb; personal fees from Amgen, Pfizer, Gilead Sciences, Pentixapharm, and Roche; grants, personal fees, and nonfinancial support from MSD and Takeda; and grants, personal fees, and nonfinancial support from Novartis. SB reports being founder, CEO and shareholder of Liqomics and personal fees and non-financial support from Bristol-Myers Squibb and Takeda outside the submitted work.
Data Availability
Primary sequencing data cannot be deposited publicly due to legal requirements and patient data protection. Upon entering a collaboration agreement and in consultation with the local ethics committee access to primary sequencing data might be granted. All secondary data derived from primary sequencing data is available within the article, supplementary information, or supplementary data files or available from the authors upon reasonable request.
